CVS Health Corp Now Looks Toward Price War In Cholesterol-Reducing Drugs Market

February 18, 2015 9:26 PM

4 0

Pharmacy-benefits managers are hoping to be able to use similar practices as those deployed by Express Scripts Holding Company (NASDAQ:ESRX), the nation’s largest pharmacy-benefits management company, to bring down the costs of medicines other than the hepatitis C treatment drugs, especially a new class of expensive cholesterol-reducing drugs.

CVS Health Corp (NYSE:CVS) has declared its intention to carefully review the pricing for PCSK9 inhibitors – a new class of injectable cholesterol treatments. From the looks of it, it appears as if the company is intent on regulating the prices of these treatments, as the cost of these drugs, which ...

Read more

To category page